Insider Selling: Billiontoone (NASDAQ:BLLN) Insider Sells 8,000 Shares of Stock

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $98.22, for a total transaction of $785,760.00. Following the transaction, the insider owned 212,000 shares of the company’s stock, valued at approximately $20,822,640. This trade represents a 3.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Billiontoone Trading Down 3.1%

Shares of BLLN traded down $3.13 during mid-day trading on Wednesday, hitting $99.26. 1,040,614 shares of the company were exchanged, compared to its average volume of 694,048. Billiontoone, Inc. has a 1-year low of $61.96 and a 1-year high of $138.70. The company has a quick ratio of 10.58, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The company has a 50 day moving average of $87.26 and a 200-day moving average of $88.18.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.33. The company had revenue of $108.39 million for the quarter, compared to analyst estimates of $95.81 million. During the same quarter last year, the company earned ($0.39) EPS. The firm’s revenue for the quarter was up 83.8% on a year-over-year basis. Equities analysts forecast that Billiontoone, Inc. will post 0.93 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on BLLN shares. JPMorgan Chase & Co. upped their price target on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, May 7th. Weiss Ratings downgraded shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 5th. Guggenheim upped their price target on shares of Billiontoone from $100.00 to $120.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. BTIG Research reduced their price target on shares of Billiontoone from $140.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Wall Street Zen upgraded shares of Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Six analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Billiontoone presently has a consensus rating of “Moderate Buy” and an average target price of $125.29.

Institutional Trading of Billiontoone

A number of hedge funds have recently bought and sold shares of the business. Rossby Financial LCC acquired a new stake in Billiontoone in the 4th quarter valued at about $25,000. Wells Fargo & Company MN acquired a new stake in Billiontoone in the 4th quarter valued at about $76,000. Smartleaf Asset Management LLC acquired a new stake in Billiontoone in the 4th quarter valued at about $80,000. Nano Cap New Millennium Growth Fund L P acquired a new stake in Billiontoone in the 4th quarter valued at about $82,000. Finally, Renaissance Capital LLC acquired a new stake in Billiontoone in the 4th quarter valued at about $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.